Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(2 sites)

United States

Memorial Sloan Kettering Cancer Center, New York, New York

MD Anderson Cancer Center, Houston, Texas